First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial

Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701

American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003

Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W. T., Smith, T. J., Baker, S., Olak, J., Stover, D. E., Strawn, J. R., Turrisi, A. T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,411

Nasogastric administration of osimertinib suspension for an epidermal growth factor receptor-mutated lung cancer causing an esophageal stricture: case report

Tani, N., Takatsuka, S., Kataoka, N., Kunimatsu, Y., Tsutsumi, R., Sato, I., Tanimura, M., Nakano, T., Tanimura, K., Kato, D., et al. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-940 · Cited by 1

Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report

Mirallas, O., Bosch-Schips, M., Pardo, N., Aubanell, A., Salcedo, M. T., Callejo, A., Iranzo, P., Tabernero, J. M., & Felip, E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837630 · Cited by 1

Dabrafenib plus trametinib treatment for a patient with BRAF V600E-mutated large-cell lung carcinoma and a poor performance status

Nakajima, Y., Nishijima, Y., Niida, A., Kiyama, K., Sasaki, A., Fujimoto, Y., Ishizuka, A., Ehara, J., Ogita, S., & Norisue, Y. (2022) · International Cancer Conference Journal · doi:10.1007/s13691-022-00556-9 · Cited by 1

EGFR mutation and ALK fusion-positive non-small cell lung cancer: a multicenter prospective cohort study in Nagano Prefecture, Japan

Kobayashi, T., Kanda, S., Tateishi, K., Morozumi, N., Yamamoto, R., Yoshiike, F., Takizawa, H., Takada, M., Yamamoto, M., Nishie, K., et al. (2023) · Oncology in Clinical Practice · doi:10.5603/ocp.2023.0038 · Cited by 1

Thérapeutiques ciblées dans le traitement des tumeurs solides

Beuzeboc, P. (2011) · Springer eBooks · doi:10.1007/978-2-8178-0021-9_5 · Cited by 1

Molecular Targeted Therapy in Lung Cancer

Ahn, M. (2014) · Hanyang Medical Reviews · doi:10.7599/hmr.2014.34.1.37 · Cited by 1

Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational study

Higashiguchi, M., Kijima, T., Morimura, O., Osa, A., Suzuki, H., Inoue, T., Kagawa, H., Ueno, K., Hirashima, T., Kumagai, T., et al. (2015) · Cancer Treatment Communications · doi:10.1016/j.ctrc.2015.11.004 · Cited by 1

A CASE OF LUNG CANCER DEVELOPED PNEUMOTHORAX DURING ADMINISTRATION OF GEFITINIB

Konno, H., Nakagawa, T., Sasaki, T., Oyama, N., Uesaka, Y., & Saito, M. (2011) · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · doi:10.3919/jjsa.72.43 · Cited by 1

Erlotinib Plus Parenteral Nutrition

Zang, Y., Fang, Z., & Li, B. (2013) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909113476930 · Cited by 1

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer

Takeda, M., Okamoto, I., & Nakagawa, K. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv471.20 · Cited by 1

Genomics and Molecular Profiling of Lung Cancer

Xu, Z. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-396967-5.00012-8 · Cited by 1

LNA™

Echwald, S. M., & Mouritzen, P. (2013) · CRC Press eBooks · doi:10.1201/b14930-10 · Cited by 1

Incorporating Pharmacogenomics in Drug Development

Yin, O. Q. P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-391918-2.00018-4 · Cited by 1

Diffusion-weighted magnetic resonance imaging-directed biopsy of a metastatic bone tumor: Lung adenocarcinoma with ALK rearrangement

Hibino, M., Otsuka, Y., Maeda, K., Horiuchi, S., Fukuda, M., & Kondo, T. (2018) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2018.05.024 · Cited by 1

Prognostic factors and first-line treatment modalities in nonagenarian patients with lung cancer

Hsu, C.-C., Huang, Y.-T., Tseng, Y.-H., Luo, Y., & Chen, Y.-M. (2018) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2018.07.013 · Cited by 1

Prise en charge thérapeutique des cancers bronchiques non à petites cellules de stades avancés mutés pour l’EGFR

Cadranel, J. L., Fallet, V., Canellas, A., Lavolé, A., Ruppert, A.-M., & Wislez, M. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30040-5 · Cited by 1

Metastases to the brain and spinal cord parenchyma

Brandsma, D., Schiff, D., Short, S. C., Maldaun, M. V. C., & Rushing, E. J. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780198869702.003.0025 · Cited by 1

[Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor].

Zhong, S. S., & Fan, Y. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.02.11

Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib

Naito, Y., & Goto, K. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2122

Traitement par chimiothérapie des cancers bronchiques non à petites cellules chez les patients fragilisés: Sujets âgés, performance status 2, VIH

Quoix, É., Fraisse, P., Mennecier, B., Prim, N., Beau‐Faller, M., Matau, C., Ducoloné, A., Molard, A., Dégot, T., Stenger, R., et al. (2013) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(13)70437-3

Developments in the Management of Advanced Non Small Cell Lung Cancer

Kopitopoulou, A., Ntanos, I., Saif, M. W., & Syrigos, K. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.41027

Targeted Therapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer—Patient Selection Changes the Fate of Gefitinib

Locke, S. R. A. I. (2010) · Clinical Medicine Reviews in Oncology · doi:10.4137/cmro.s3276

Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer

Wilson, C. (2010) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s9974

Targeted Therapy For Lung Cancer: Reviewing the Cost and Its Effect on Treatment Decisions

Lim, C. H., Sergi, M., & Leighl, N. B. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.36

Traitement des CBNPC au stade métastatique. Acquis et bonnes pratiques

Pérol, M. (2013) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(13)70436-1

Acute leukemia secondary to lung cancer in an elderly

Tamura, T., Miyazaki, K., Yoshida, C., Kagohashi, K., & Satoh, H. (2014) · European Geriatric Medicine · doi:10.1016/j.eurger.2014.06.032

EGFR Signaling and Radiation

Dunn, E., Huang, S., & Harari, P. M. (2011) · Springer eBooks · doi:10.1007/978-1-4419-8044-1_10

Traitement du cancer bronchique non à petites cellules au stade avancé chez le sujet âgé

Corre, R. (2012) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(12)70313-0

Prise en charge des cancers bronchiques non à petites cellules au stade métastatique : évolution du traitement de première ligne

Pérol, M., Odier, L., & Arpin, D. (2009) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(09)72513-3

Models of partnership between the pharmaceutical and diagnostics industries around companion diagnostics for cancer and beyond

Ensinger, C. (2011) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2011.552497

Pharmacotherapy for treatment of lung cancer in the elderly

van Veggel, B. A. M. H., Biesma, B., & Smit, E. F. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1028357

Les outils biologiques en pratique : aide au diagnostic, au pronostic et au traitement du cancer bronchique

Mazières, J., Rouquette, I., & Brouchet, L. (2009) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(09)72497-8

Chemotherapy for advanced non-small-cell lung cancer patients with poor performance

Kim, K., & Kim, S. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.48

Quel traitement de première ligne en cas de mutation activatrice de l’EGFR dans les cancers bronchiques non à petites cellules (CBNPC) disséminés ?

Emery, M., & Cadranel, J. L. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70530-0

Prise en charge des sujets fragiles Savoir adapter le traitement du cancer broncho-pulmonaire à l’état général, à la défaillance rénale, hépatique et au sujet immunodéficient (transplanté, VIH)

Moro‐Sibilot, D., Toffart, A., & Coudurier, M. (2011) · Springer eBooks · doi:10.1007/978-2-287-99041-0_16

Treatment of Frail Patients and Octogenarians with Advanced NSCLC

Gridelli, C., Maione, P., & Rossi, A. (2013) · Springer eBooks · doi:10.1007/978-0-85729-793-8_15

A Phase I Study of Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2

Kim, Y. H., Kubota, K., Goto, K., Yoh, K., Niho, S., Ohmatsu, H., Saijo, N., & Nishiwaki, Y. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp061

Gefitinib: Re-Emerging from the Shadows

Martin, P., Owen, S. P., & Leighl, N. B. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.42

Leczenie niedrobnokomórkowego raka płuca w stadium zaawansowanym u osób starszych

Knetki‐Wróblewska, M., Płużański, A., & Krzakowski, M. J. (2012) · Via Medica Journals

Traitement des progressions tumorales dans le cancer du poumon muté EGFR : à propos d'une cohorte de patients métastatiques suivis à l'Institut Bergonié

Domblides, C. (2015) · HAL

Prise en charge des patients de Performans Status 2 atteints d'un cancer bronchique non à petites cellules métastatique

Leduc, C., & Quoix, É. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30035-0

Une ≪ population spéciale ≫ : les sujets âgés

Greillier, L., Tomasini, P., Fournier, C., & Barlési, F. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30036-2

The Role of Targeted Therapy in Special Populations

Larkin, J., & Gore, M. E. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1622-1_19

Gefitinib for Advanced Non–Small-Cell Lung Cancer

Chen, L.-C. (2009) · Journal watch · doi:10.1056/oh200904280000001

Contrôle de la signalisation oncogénique du mutant L858R de l'EGFR par la protéine

Ozenne, P. (2011)

A Case of Advanced Lung Adenocarcinoma with Paranasal Sinus Metastases, in Which Gefitinib Was Effective as First-line Therapy and Cyberknife® Was Efficacious for Local Control

Honda, T., Saito, H., Murakami, S., Hasegawa, C., Isobe, T., & Yamada, K. (2011) · Haigan · doi:10.2482/haigan.51.5

Lepidic-predominant Adenocarcinoma Accompanied by Empyema

Misaki, N., Kita, Y., Yoji, K., Mito, F., & Kishimoto, N. (2013) · Haigan · doi:10.2482/haigan.53.846

3. Recent Progress for Chemotherapy in Advanced Non-small Cell Lung Cancer.

Takahashi, K. (2011) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.100.763

A Young Adult Case of Poorly Differentiated Lung Adenocarcinoma Showing the Resistance Mutation T790M of EGFR before Treatment with Tyrosine Kinase Inhibitors.

Okamura, T., Shibusawa, N., Koga, Y., Horiguchi, N., Ogashiwa, T., Satoh, K., Hisada, T., Satoh, T., 石塚, 真., & Mori, M. (2011) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.100.1959

A case of no small cell lung carcinoma with leptomeningeal metastasis by elrotinib succeeded

Saito, E. (2013) · Palliative Care Research · doi:10.2512/jspm.8.554

Quel choix de traitement en première ligne ?

Moro‐Sibilot, D. (2011) · Revue de Pneumologie Clinique · doi:10.1016/s0761-8417(11)70006-2

Intérêt de l’ADN tumoral circulant dans le cancer pulmonaire : à propos d’un cas

Amrane, K., Gac, G. L., Descourt, R., & Quéré, G. (2016) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2016.02.007

First-line therapy of advanced non-small cell lung cancer with activatingEGFRmutations

Zhou, C. (2012) · Informa Healthcare eBooks · doi:10.3109/9781841848679.007

5. The Recent Progress of Lung Cancer Chemotherapy

Yamamoto, N., & Akamatsu, H. (2016) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.105.493

The Epidermal Growth Factor Receptor (EGFR) Mutation Tests

Hagiwara, K. (2009) · Haigan · doi:10.2482/haigan.49.928

Les populations particulières : les personnes âgées atteintes d’un cancer bronchique

Leduc, C., Mennecier, B., Ducoloné, A., Matau, C., Fraisse, P., & Quoix, É. (2016) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30130-6

Treatment of advanced non-small cell lung cancer in the elderly

Knetki‐Wróblewska, M., Płużański, A., & Krzakowski, M. J. (2011) · Oncology in Clinical Practice

Molecular targeted therapy of lung cancer

Hashimoto, S. (2015) · Tenri Medical Bulletin · doi:10.12936/tenrikiyo.18-009

Les patients avec indice de performance supérieur à 1

Berghmans, T. (2017) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(17)30062-9

Prise en charge du CBNPC chez les sujets âgés

Corre, R., & Caer, H. L. (2017) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(17)30061-7

AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES

Карабина, Е. В., Lubchenko, L. N., & Давыдов, М. М. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-14-46-55

Cancer in the Very Elderly and Management

Thiruthaneeswaran, N., Morris, L. M., & Jayamohan, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-96998-5_20

Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer

Ramalingam, S. S., Pillai, R. N., Reinmuth, N., & Reck, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00044-5

Outcomes of gefitinib therapy for disease recurrence in medically inoperable stage I lung adenocarcinoma patients with active EGFR mutations receiving stereotactic body radiotherapy: a single-institute retrospective study

Kashiwabara, K., Semba, H., Fujii, S., & Tsumura, S. (2019) · International Journal of Surgery Oncology · doi:10.1097/ij9.0000000000000072

High-flow Nasal Cannula Oxygenation During Diagnostic Bronchoscopy in a Patient with Pulmonary Lymphangitic Carcinomatosis and Acute Respiratory Failure

Sakurahara, D., Himeji, D., Kawaguchi, T., Tanaka, G., Yamanaka, A., Shimao, Y., & Marutsuka, K. (2019) · 気管支学 : 日本気管支研究会雑誌 · doi:10.18907/jjsre.41.5_473

Traitement des cancers bronchiques non à petites cellules de stades avancés mutés EGFR: quelle(s) séquence(s) ?

Cadranel, J. L., Fallet, V., Baldacci, S., & Cortot, A. B. (2019) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(19)30106-5

In vitro and in vivo investigation of the anticancer activity and molecular mechanisms of disulfiram in non-small cell lung cancer

Butcher, K. (2019) · Wolverhampton Intellectual Repository and E-Theses (University of Wolverhampton)

Rôle de l’évaluation gériatrique dans le traitement des CBNPC au stade métastatique

Corre, R. (2012) · ONCOLOGIE · doi:10.1007/s10269-012-2155-8

Populations particulières : patients de Performance Status 2 ou plus

Gounant, V., Soussi, G., Pluvy, J., Brosseau, S., Hachon, L., Haberer-Guillerm, S., Mordant, P., & Zalcman, G. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30107-5

Effectiveness of Late Line Palliative Chemotherapy by Specialised Approach to Cancer of Unknown Primary: A Case Report

Sato, I., Nakaya, N., Obara, Y., Kurosaka, N., Ueno, S., & Nakajima, H. (2020) · Journal of Cancer Treatment and Research · doi:10.11648/j.jctr.20200804.13

南ら"EBUS-TBNAでEGFR変異検出が可能であった全身状態不良高齢者肺腺癌の1症例"

奥仲, 哲. (2011) · 気管支学 : 日本気管支研究会雑誌 · doi:10.18907/jjsre.33.1_14

Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGR

Cadranel, J. L., Fallet, V., Baldacci, S., & Cortot, A. B. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00106-3

EGFR-Targeted Therapies in Non-small Cell Lung Cancer

Cappuzzo, F. (2014) · Springer eBooks · doi:10.1007/978-3-319-03059-3_5

A Strategy for the Lung Cancer Treatment in Elderly Patients

ichikawa, Y., Ota, S., & 研二, 江. (2012) · Nihon Kikan Shokudoka Gakkai Kaiho · doi:10.2468/jbes.63.374

Lung Adenocarcinoma in a Patient with a Reduced Performance Status due to Carcinomatous Meningitis That Showed a Remarkable Response to Osimertinib: a Case Report

Murao, K., Mori, Y., Kobayashi, T., Takahashi, Y., Ishikawa, T., Asai, Y., Ikeda, K., Kuronuma, K., Tanaka, Y., & Chiba, H. (2021) · Haigan · doi:10.2482/haigan.61.946

Targeted Therapies

Daste, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-22009-9_772

Non-Small Cell Lung Cancer in Older Adults with Frailty

Gomes, F., Banfill, K., Billè, A., Fraser, S., & Banna, G. L. (2022) · Springer eBooks · doi:10.1007/978-3-030-89162-6_18

Targeted Therapies

Daste, A. (2020) · Springer eBooks · doi:10.1007/978-3-319-69892-2_772-1

EGFR Mutant

Kobayashi, K., & Kagamu, H. (2017) · Springer eBooks · doi:10.1007/978-981-10-2002-5_10

Effects of the ABCG2 C421A Polymorphism on Plasma Gefitinib ConcentrationPreprint

Sakamoto, S. (2019) · Research Square · doi:10.21203/rs.2.10916/v1

Les populations particulières : les personnes âgées atteintes d’un cancer bronchique

Quoix, É. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30038-7

Drug interaction (54. Drug interaction in the process of absorption and excretion of anticancer drugs)

Danzako, M., Esumi, S., & Zamami, Y. (2022) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.134.102

Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGR

Cadranel, J. L., Fallet, V., Baldacci, S., Duruisseaux, M., & Cortot, A. B. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00119-7 · Cited by 1

Populations particulières : patients de Performance Status 2 ou plus

Gounant, V., Brosseau, S., Bizot, A., Vauchier, C., Khrouf, S., Hachon, L., Haberer-Guillerm, S., Mordant, P., & Zalcman, G. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00137-9

Supplementary Appendix 1 from Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009

Jankú, F., Berry, D. A., Gong, J., Parsons, H. A., Stewart, D. J., & Kurzrock, R. (2023) · doi:10.1158/1078-0432.22445487

Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGFR

Cadranel, J. L., Fallet, V., Baldacci, S., Duruisseaux, M., & Cortot, A. B. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00139-8

Populations particulières : patients de performance status 2 ou plus

Gounant, V., Brosseau, S., Guezour, N., Vauchier, C., Ferreira, D. L., Nicolas, L., Haberer-Guillerm, S., Mordant, P., & Zalcman, G. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00167-2

The Race Against Time: Evaluating the Speed of Gene Panel Result Delivery in NSCLC Patient ManagementPreprint

Kunimasa, K., Tamiya, M., Inoue, T., Kawamura, T., Miyazaki, A., Kanzaki, R., Maniwa, T., Honma, K., Okami, J., & Nishino, K. (2023) · Research Square · doi:10.21203/rs.3.rs-3560728/v1

Remarkable Response to Dabrafenib and Trametinib in a V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) V600E-Mutated Lung Adenocarcinoma Patient With Poor Performance Status and Respiratory Failure: A Case Report

Anai, S., Isa, K., Chibana, R., Ueno, S., & Sato, Y. (2024) · Cureus · doi:10.7759/cureus.75217

Populations particulières : Patients de Performance Status 2 et plus

Gounant, V., Alvarez, L., Xu, Y. M., Mehlman, C., Nicolas, L., Haberer-Guillerm, S., Mordant, P., & Zalcman, G. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00091-6

Le cancer du poumon du sujet âgé

Lozano, S., & Mazières, J. (2011) · Springer eBooks · doi:10.1007/978-2-8178-0142-1_12

Additional file 4 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915426

Additional file 2 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915417

Additional file 1 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915414

Additional file 1 of Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study

Miyawaki, T., Kenmotsu, H., Kodama, H., Nishioka, N., Miyawaki, E., Mamesaya, N., Kobayashi, H., Omori, S., Ko, R., Wakuda, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17054721

Additional file 3 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915420

Additional file 1 of A systematic review of the budget impact analyses for antitumor drugs of lung cancer

Han, L., Zhang, X., Fu, W., Sun, C., Zhao, X.-M., Zhou, L.-R., & Liu, G.-X. (2020) · Figshare · doi:10.6084/m9.figshare.13311058

Maximum Efficacy of Immune Checkpoint Inhibitors in Esophageal Cancer Patients With Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment

平澤, 優. (n.d.) · Institutional Repositories DataBase (IRDB)

Rôle des calpaïnes extracellulaires dans la progression des adénocarcinomes lépidiques

Ruppert, A.-M. (2015) · theses.fr (ABES) · doi:10.70675/6082601cze5b6z41e9zb588zf90c85ff07c9

Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis

Nieves, A. S., Daele, M. V., Konsker, H. B., & Yarden, Y. (2026) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2024.0512

Clinical outcomes of 1st-line gefitinib for patients with advanced NSCLC harboring EGFR mutations and poor PS

Miura, Y., Minato, K., Fujimoto, S., Sunaga, N., & Yamada, M. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv472.138

First-line gefitinib for poor PS patients with EGFR mutations

Kobayashi, K., Inoue, A., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., Ando, M., Gemma, A., Morita, S. H., & Hagiwara, K. I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8070 · Cited by 3

Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.

Okuma, Y., Hosomi, Y., Nagamata, M., Yamada, Y., Sekihara, K., Kato, K., Hishima, T., & Okamura, T. (2013) · PubMed · Cited by 12

Clinical Outcomes After First-Line Egfr-Tki for Patients with Nsclc, Egfr Mutation, and Poor Performance Status

Nagamata, M., Okuma, Y., Sunami, K., Hosomi, Y., & Okamura, T. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu436.90

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

Inoue, A., Suzuki, T., Fukuhara, T., Maemondo, M., Kimura, Y., Morikawa, N., Watanabe, H., Saijo, Y., & Nukiwa, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4692 · Cited by 509